ConductScience.org, home

Gene · 5427

POLE2: DNA polymerase epsilon 2, accessory subunit

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. POLE2: DNA polymerase epsilon 2, accessory subunit. Genes, record 5427. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5427

On this page

Gene

Symbol
POLE2
HGNC
Name
DNA polymerase epsilon 2, accessory subunit
HGNC
NCBI Gene ID
5427
NCBI Gene
HGNC ID
HGNC:9178
HGNC
Ensembl
ENSG00000100479
NCBI Gene
Aliases
DPE2
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P56282DNA polymerase epsilon subunit 25274Ensembl, GeneID, HGNC

Source UniProt

Patents15

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1458452P56282Espacenet
EP 4641202 A22025-10-294318P56282Espacenet
KR 1020250017231 A2025-02-044318P56282Espacenet
US 12006548 B22024-06-11584P56282Espacenet
US 11446398 B22022-09-2064942P56282Espacenet
JP 2022524081 A2022-04-27167913P56282Espacenet
US 10975437 B22021-04-13584P56282Espacenet
JP 2020062004 A2020-04-231080P56282Espacenet
JP 2019054813 A2019-04-11238887P56282Espacenet
US 10190169 B22019-01-29584P56282Espacenet

1 to 10 of 15

See all 15 patents

Drugs7

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ASPACYTARABINECHEMBL4297599DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL
CLOFARABINECHEMBL1750DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL
CYTARABINECHEMBL803DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL
FLUDARABINE PHOSPHATECHEMBL1096882DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL
GEMCITABINECHEMBL888DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL
GEMCITABINE HYDROCHLORIDECHEMBL1637DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL
TROXACITABINECHEMBL359164DNA polymerase (alpha/delta/epsilon) inhibitorINHIBITORChEMBL

Trials4,186

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07604766GEMCITABINEPHASE3ClinicalTrials.gov
NCT07604233CYTARABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07603557FLUDARABINE PHOSPHATEPHASE2ClinicalTrials.gov
NCT07602140GEMCITABINEPHASE2ClinicalTrials.gov
NCT07598318GEMCITABINEPHASE2/PHASE3ClinicalTrials.gov
NCT07588360CYTARABINEClinicalTrials.gov
NCT07583888CYTARABINEPHASE2/PHASE3ClinicalTrials.gov
NCT07579195GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07575191GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07570849GEMCITABINEPHASE2ClinicalTrials.gov

1 to 10 of 4,186

See all 4,186 trials

NIH grants373

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePOLE2 papersNewest fiscal year
P30CA006973Regional Oncology Research Center32025
P30CA008748Cancer Center Support Grant32025
P30CA036727Buffett Cancer Center Support Grant22025
P30CA046934University of Colorado Cancer Center Support Grant22025
P30CA082709Indiana University Melvin and Bren Simon Comprehensive Cancer Center Support Grant22025
P30DK078392Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease22025
R01ES028271Investigation of human DNA polymerase epsilon variants22025
R01GM134681The role of DNA damage tolerance pathways in human cells22025
R35GM127026Cell Signaling and Cell Decisions22025
ZIAAI001222Characterization of the cellular and molecular bases of inborn errors of immunity22025

1 to 10 of 373Source NIH's project files

See all 373 nih grants

Papers543

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma.Cancer Gene Ther202642773249PubTator, text miningPubMed
Multi-omics identification of a programmed cell death-related signature and potential target P4HB for bladder cancer based on a 101-combination machine learning and experimental validation.Clin Exp Med202641925913PubTator, text miningPubMed
Role of POLE2/GINS1-mediated AKT/mTOR pathway in RCC autophagy, proliferation, and metastasis: evidences from bioinformatic, clinical, and experimental data.Apoptosis202641893924PubTator, text miningPubMed
Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure.Anticancer Res202641760274PubTator, text miningPubMed
Charting the multilevel molecular response to palbociclib in ER-positive breast cancer.NAR Cancer202641710088PubTator, text miningPubMed
Exploring the role of CCT7 in prognosis, cell cycle regulation, and immune microenvironment remodeling of lung adenocarcinoma based on multi-omics datasets and functional experiments.Biochim Biophys Acta Gen Subj202641429196PubTator, text miningPubMed
Data-Driven Discovery of a Key Regulator Cyclin A2 as a Promising Therapeutic Target in Hormone-Sensitive Cancers.Mol Biotechnol202640936038PubTator, text miningPubMed
Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer.Curr Issues Mol Biol202541614789PubTator, text miningPubMed
The non-catalytic DNA polymerase ε subunit is an NPF motif recognition protein.Nat Commun202541390769PubTator, text miningPubMed
Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.Eur J Med Chem202540961586PubTator, text miningPubMed

1 to 10 of 543

See all 543 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/5427

GET https://conductscience.org/api/genes/v1/5427/patents